1 / 22

Congenital Muscular Dystrophy Biomarker Discovery

Congenital Muscular Dystrophy Biomarker Discovery. James Collins MD, PhD Assistant Professor Division of Neurology Cincinnati Children’s Hospital Medical Center. Disclosures. Research Foundation Grant: Cure Congenital Muscular Dystrophies partnered with S.A.M. ( www.curecmd.org ).

nakeisha
Télécharger la présentation

Congenital Muscular Dystrophy Biomarker Discovery

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Congenital Muscular Dystrophy Biomarker Discovery James Collins MD, PhD Assistant Professor Division of Neurology Cincinnati Children’s Hospital Medical Center

  2. Disclosures Research Foundation Grant: Cure Congenital Muscular Dystrophies partnered with S.A.M. (www.curecmd.org)

  3. Biomarker “A characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention.” Biomarkers Definition Working Group, NIH Clin Pharmacol Ther 2001;69:89-95

  4. Biomarker • Clinical practice • identify risk for or diagnose a disease • assess disease severity or progression • predict prognosis • or guide treatment http://www.biomarkersconsortium.org/index.php?option=com_content&task=view&id=132&Itemid=184

  5. Biomarker http://www.prostateuk.org/psa/psa.htm

  6. CMD Biomarker Discovery Liotta, et al. Nature, 2003. Taniguchi, M. et al., Biochem Biophys Res Commun, 2006. 342(2): p. 489-502.

  7. Biomarker • Drug development • How does a drug work in the body • Is the drug safe or effective • What dose of the drug is effective • Response to a treatment • Treatment trial - FDA regulatory approval process http://www.biomarkersconsortium.org/index.php?option=com_content&task=view&id=132&Itemid=184

  8. Drug development Measured to/ Substitute for affects Therapeutic Intervention Clinical Endpoint Biomarker Beneficial or Harmful Effects Not Measured by a Biomarker Effects of therapeutic interventions on biomarkers and clinical endpoints in clinical trials. Biomarkers Definition Working Group, NIH. Clin Pharmacol Ther 2001;69:89-95

  9. Biomarker development • Discovery phase • Proximal fluids, cell lines, animal models, tissue of interest • candidates • Qualification phase • Human plasma • Confirm candidate molecules • Verification phase • Population-based (specificity) • Validation and clinical assay development • Sensitivity and specificity Rifai, N., M.A. Gillette, and S.A. Carr, Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol, 2006. 24(8): p. 971-83.

  10. Biomarker discovery • Genomics • Relevant disease genes, expression profiles, signaling pathways • Proteomics • Protein expression and post-translational modifications • Metabolomics • small molecule metabolites specific to disease • Imaging • Imaging changes reflect disease state

  11. RNA Expression Profiling of Blood from Humans Apply RNA to MICROARRAYS Whole Blood GeneSpring, Partek and NCI public software to analyze data DAVID, KEGG and others for pathways STORE -700C Isolate RNA

  12. Cluster analysis of genes [with ≥ 2.5-fold change] blood of DMD compared to healthy age matched males) Wong, B., et al., Gene expression in blood of subjects with Duchenne muscular dystrophy. Neurogenetics, 2009. 10(2): p. 117-25.

  13. DMD Gene expression profile Steroid treatment effect Lit L. et al., Pharmacogenomics J, 2009. 9(6): p. 411-8.

  14. Proteomics approach http://biogratech.com/resources/From+blood+withdrawal+to+RBC+proteomics.PNG

  15. Gene expression profiling CMD Merosin-deficient mice models (dy/dy) muscle • contractile proteins • shift towards embryonic and perinatal myosin forms • genes involved in cellular adhesion • procollagen genes • genes related to immune response and complement activation • van Lunteren, E. et al., Physiol Genomics, 2006. 25(1): p. 85-95.

  16. Gene expression profiling CMD Fukuyama-type CMD and Merosin - deficient patients expression profile in muscle • up-regulation • extracellular matrix and • basement membrane component genes • unique expression pattern • dystrophin-deficient muscle • Unique profile of FCMD compared to MDC1A Taniguchi, M., et al.Biochem Biophys Res Commun, 2006. 342(2): p. 489-502

  17. Proteomics - CMD • no published proteomic studies • 14th international congress WMS society 2009, Geneva, Switzerland • Abstract • Col6a1-/- mice vs WT using 2D-DGE showed 37 proteins differentially expressed in diaphragm Bovelenta et al. NMD 2009 EM.P.5.01; doi:10.1016/j.nmd.2009.06.268

  18. Going Forward: “Bench to Bedside” • merosin deficient CMD (proteomic and gene expression profiling) • CMD subtypes • Verification: animal models / biobank tissues • Qualification: therapeutic interventions • Validation • Teaming up with multiple academic centers, private and governmental agencies • Biomarker correlation with natural history outcome measures, imaging, and functional mobility scales • Goal: biomarker profile assay use as surrogate end point

  19. Challenges • Access to patients and samples • Heterogeneity • Progressive disorders • defining functional endpoints • Funding / incentives

  20. Carsten Bonnemann Kate Bushby Ton DeGrauw Prasad Devarajan Andrew Hershey Anne Rutkwoski Brenda Wong CMD families Acknowledgements

  21. References • Biomarkers Definition Working Group, NIH Clin Pharmacol Ther 2001;69:89-95 • Rodland K. Systems biology and biomarker discovery. Disease Markers 2010;28:195-7 • http://www.biomarkersconsortium.org/index.php?option=com_content&task=view&id=132&Itemid=184 • Sorani et al. Clinical and biological data integration for biomarker discovery Drug Discovery Today 2010, doi:10.1016/j.drudis.2010.06.005 • Fuller, H.R., et al., Valproate and Bone Loss: iTRAQ Proteomics Show that Valproate Reduces Collagens and Osteonectin in SMA Cells. J Proteome Res, 2010. • Hampel, H., et al., Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov, 2010. 9(7): p. 560-74. • Rifai, N., M.A. Gillette, and S.A. Carr, Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol, 2006. 24(8): p. 971-83. • Wong, B., et al., Gene expression in blood of subjects with Duchenne muscular dystrophy. Neurogenetics, 2009. 10(2): p. 117-25. • Lit, L., et al., Corticosteroid effects on blood gene expression in Duchenne muscular dystrophy. Pharmacogenomics J, 2009. 9(6): p. 411-8. • van Lunteren, E., M. Moyer, and P. Leahy, Gene expression profiling of diaphragm muscle in alpha2-laminin (merosin)-deficient dy/dy dystrophic mice. Physiol Genomics, 2006. 25(1): p. 85-95 • Taniguchi, M., et al., Expression profiling of muscles from Fukuyama-type congenital muscular dystrophy and laminin-alpha 2 deficient congenital muscular dystrophy; is congenital muscular dystrophy a primary fibrotic disease? Biochem Biophys Res Commun, 2006. 342(2): p. 489-502. • Bovelenta et al. Gene expression and proteome profiles in Col6a1-/- mice, a model of Ullrich congenital muscular dystrophy. NMD 2009 EM.P.5.01; doi:10.1016/j.nmd.2009.06.268 • Liotta, L.A., M. Ferrari, and E. Petricoin, Clinical proteomics: written in blood. Nature, 2003. 425(6961): p. 905.

More Related